Literature DB >> 27927986

Lipopolysaccharide (LPS)-stimulated iNOS Induction Is Increased by Glucosamine under Normal Glucose Conditions but Is Inhibited by Glucosamine under High Glucose Conditions in Macrophage Cells.

Ji-Sun Hwang1, Mi-Youn Kwon1, Kyung-Hong Kim1, Yunkyoung Lee2, In Kyoon Lyoo2, Jieun E Kim2, Eok-Soo Oh3, Inn-Oc Han4.   

Abstract

We investigated the regulatory effect of glucosamine (GlcN) for the production of nitric oxide (NO) and expression of inducible NO synthase (iNOS) under various glucose conditions in macrophage cells. At normal glucose concentrations, GlcN dose dependently increased LPS-stimulated production of NO/iNOS. However, GlcN suppressed NO/iNOS production under high glucose culture conditions. Moreover, GlcN suppressed LPS-induced up-regulation of COX-2, IL-6, and TNF-α mRNAs under 25 mm glucose conditions yet did not inhibit up-regulation under 5 mm glucose conditions. Glucose itself dose dependently increased LPS-induced iNOS expression. LPS-induced MAPK and IκB-α phosphorylation did not significantly differ at normal and high glucose conditions. The activity of LPS-induced nuclear factor-κB (NF-κB) and DNA binding of c-Rel to the iNOS promoter were inhibited under high glucose conditions in comparison with no significant changes under normal glucose conditions. In addition, we found that the LPS-induced increase in O-GlcNAcylation as well as DNA binding of c-Rel to the iNOS promoter were further increased by GlcN under normal glucose conditions. However, both O-GlcNAcylation and DNA binding of c-Rel decreased under high glucose conditions. The NF-κB inhibitor, pyrrolidine dithiocarbamate, inhibited LPS-induced iNOS expression under high glucose conditions but it did not influence iNOS induction under normal glucose conditions. In addition, pyrrolidine dithiocarbamate inhibited NF-κB DNA binding and c-Rel O-GlcNAcylation only under high glucose conditions. By blocking transcription with actinomycin D, we found that stability of LPS-induced iNOS mRNA was increased by GlcN under normal glucose conditions. These results suggest that GlcN regulates inflammation by sensing energy states of normal and fuel excess.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  NF-κB; O-GlcNAcylation; O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT); glucose; inflammation

Mesh:

Substances:

Year:  2016        PMID: 27927986      PMCID: PMC5290947          DOI: 10.1074/jbc.M116.737940

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

3.  High glucose increases nitric oxide generation in lipopolysaccharide-activated macrophages by enhancing activity of protein kinase C-α/δ and NF-κB.

Authors:  Kuo-Feng Hua; Szu-Hsuan Wang; Wei-Chih Dong; Chai-Yi Lin; Chen-Lung Ho; Tzu-Hua Wu
Journal:  Inflamm Res       Date:  2012-06-16       Impact factor: 4.575

Review 4.  Transcriptional regulation via the NF-kappaB signaling module.

Authors:  A Hoffmann; G Natoli; G Ghosh
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

5.  Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway.

Authors:  J N Gouze; A Bianchi; P Bécuwe; M Dauça; P Netter; J Magdalou; B Terlain; K Bordji
Journal:  FEBS Lett       Date:  2002-01-16       Impact factor: 4.124

6.  Glucosamine exerts a neuroprotective effect via suppression of inflammation in rat brain ischemia/reperfusion injury.

Authors:  So-Young Hwang; Joo-Hyun Shin; Ji-Sun Hwang; Song-Yi Kim; Jin-A Shin; Eok-Soo Oh; Seikwan Oh; Jung-Bin Kim; Ja-Kyung Lee; Inn-Oc Han
Journal:  Glia       Date:  2010-11-15       Impact factor: 7.452

7.  Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes.

Authors:  P Mohanty; W Hamouda; R Garg; A Aljada; H Ghanim; P Dandona
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

8.  Molecular cloning and analysis of the rat inducible nitric oxide synthase gene promoter in aortic smooth muscle cells.

Authors:  H Zhang; X Chen; X Teng; C Snead; J D Catravas
Journal:  Biochem Pharmacol       Date:  1998-06-01       Impact factor: 5.858

9.  Regulation of Akt signaling by O-GlcNAc in euglycemia.

Authors:  Yudi A Soesanto; Bai Luo; Deborah Jones; Rodrick Taylor; J Scott Gabrielsen; Glendon Parker; Donald A McClain
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-08-26       Impact factor: 4.310

10.  Differential metabolic effects of glucosamine and N-acetylglucosamine in human articular chondrocytes.

Authors:  A R Shikhman; D C Brinson; J Valbracht; M K Lotz
Journal:  Osteoarthritis Cartilage       Date:  2009-03-24       Impact factor: 6.576

View more
  22 in total

Review 1.  Too sweet to resist: Control of immune cell function by O-GlcNAcylation.

Authors:  Tristan de Jesus; Sudhanshu Shukla; Parameswaran Ramakrishnan
Journal:  Cell Immunol       Date:  2018-06-02       Impact factor: 4.868

2.  Hexokinase 1 cellular localization regulates the metabolic fate of glucose.

Authors:  Adam De Jesus; Farnaz Keyhani-Nejad; Carolina M Pusec; Lauren Goodman; Justin A Geier; Joshua S Stoolman; Paulina J Stanczyk; Tivoli Nguyen; Kai Xu; Krishna V Suresh; Yihan Chen; Arianne E Rodriguez; Jason S Shapiro; Hsiang-Chun Chang; Chunlei Chen; Kriti P Shah; Issam Ben-Sahra; Brian T Layden; Navdeep S Chandel; Samuel E Weinberg; Hossein Ardehali
Journal:  Mol Cell       Date:  2022-03-18       Impact factor: 17.970

Review 3.  O-GlcNAcylation regulation of cellular signaling in cancer.

Authors:  Lorela Ciraku; Emily M Esquea; Mauricio J Reginato
Journal:  Cell Signal       Date:  2021-11-17       Impact factor: 4.315

4.  Impact of a long-term high-glucose environment on pro-inflammatory responses in macrophages stimulated with lipopolysaccharide.

Authors:  Tokiko Suzuki; Shigeyuki Yamashita; Kohshi Hattori; Naoyuki Matsuda; Yuichi Hattori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-17       Impact factor: 3.000

5.  Glucosamine improves survival in a mouse model of sepsis and attenuates sepsis-induced lung injury and inflammation.

Authors:  Ji-Sun Hwang; Kyung-Hong Kim; Jiwon Park; Sang-Min Kim; Hyeongjin Cho; Yunkyoung Lee; Inn-Oc Han
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

6.  In vitro and in vivo anti-inflammatory activity of Tetrastigma sulcatum leaf extract, pure compound and its derivatives.

Authors:  Ravindra Jagannath Waghole; Ashwini Vivek Misar; Neha Shashikant Kulkarni; Feroz Khan; Dattatraya Gopal Naik; Sachin Hanmant Jadhav
Journal:  Inflammopharmacology       Date:  2022-01-22       Impact factor: 4.473

Review 7.  O-GlcNAcylation in immunity and inflammation: An intricate system (Review).

Authors:  Yu Li; Mingzheng Xie; Lili Men; Jianling Du
Journal:  Int J Mol Med       Date:  2019-06-11       Impact factor: 4.101

8.  Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.

Authors:  Wenhui Jin; Longhe Yang; Zhiwei Yi; Hua Fang; Weizhu Chen; Zhuan Hong; Yiping Zhang; Guangya Zhang; Long Li
Journal:  Mar Drugs       Date:  2020-04-21       Impact factor: 5.118

9.  Glucosamine prevents polarization of cytotoxic granules in NK-92 cells by disturbing FOXO1/ERK/paxillin phosphorylation.

Authors:  Janja Božič; Veronika Stoka; Iztok Dolenc
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

10.  Toll-like receptor 4/nuclear factor-kappa B pathway is involved in activating microphages by polysaccharides isolated from Fagopyrum esculentum.

Authors:  Zhen Chen; Leilei Yu; Xiaoniao Cai; Fangpeng Ye; Peisheng Jin
Journal:  Bioengineered       Date:  2019-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.